摘要
目的：比较国产卡维地洛与拉贝洛尔降压疗效及安全性。方法：轻、中度高血压病病人３９９例（男性 ２２８例，女性 １７１例；年龄 ５２ ａ± ｓ ９ ａ），其中２００例采用随机、单盲、平行对照方法，卡维地洛与拉贝洛尔组各 １００例，起始剂量分别为 １０ ｍｇ，ｐｏ，ｂｉｄ与 ５０ ｍｇ，ｐｏ， ｂｉｄ， ２ ｗｋ后按血压决定维持原量或增加到 ２０ ｍｇ，ｐｏ， ｂｉｄ或 １００ ｍｐ，ｐｏ， ｂｉｄ，总疗程 ４ ｗｋ。开放组 １９９例服卡维地洛 １０～２０ ｍｇ，ｐｏ， ｂｉｄ × ４ ｗｂ。其中 ４９例延长到 ６ ｍｏ。结果：随机单盲各１００例用药 １ｗｋ血压、心率均明显下降，治疗 ４ ｗｂ总有效率分别为 ７６％及 ６６％，卡维地洛组优于拉贝洛尔组（ Ｐ＜ ０． ０５）。用卡维地洛共 ２９９例总有效率 ８６． ０％。开放组中 ４９例降压从 ４ ｗｋ～６ ｍｏ呈稳定下降。 ２药不良反应依次为 １５％及１３％，均较轻，可耐受。结论： ２药均是治疗轻、中度高血压病的有效而安全的药物，卡维地洛略优于拉贝洛尔。
AIM: To evaluate the efficacy and safety of carvedilol and labetalol in treating essential hypertension. METHODS: Three hundred and ninety-nine patients with mild to moderate essential hypertension (M 228, F 171, age; 53 a +- s 9 a) were studied. Two hundred Patients received Carvedilol (n = 100, 10 mg, po, bid) and labetalol (n = 100, 50 mg, po bid) in a single blind randomized parallel design. Another 199 patients received carvedilol in open trial, 10-20 mg, po, bid for 4 wk and among them 49 patients who succeed to response to carvedilol treatment continued up to 6 mo, the doses of Carvedilol and labetalol were (remained as before or increased) from 10-20 mg and 50-100 mg, po, bid, respectively after 2 wk treatment according to the blood pressure. RESULTS: The blood pressure and heart rate of 200 Patients in a single blind randomized parallel-design were significanty decreasing since 1 wk after receiving hath carvedilol and labetalol and the response rateS (defined as a decrease in sitting DBP to
出处
《中国新药与临床杂志》
CAS
CSCD
北大核心
2000年第2期81-84,共4页
Chinese Journal of New Drugs and Clinical Remedies
